id	author	title	date	pages	extension	mime	words	sentences	flesch	summary	cache	txt
cord-275889-4qwp3um1	Guarnieri, M.	Subcutaneous Implants of a Cholesterol-Triglyceride-Buprenorphine Suspension in Rats	2017-04-09		.txt	text/plain	6861	354	55	The intended label dose of 0.65 mg/kg, which provides 2-3 days of clinically significant blood levels of drug, was established in bioequivalence trials and efficacy studies to be described using male and female rats. In the single-dose phase of the trials, 4 groups of 8 rats (4 male, 4 female) were dosed after surgery (described below) with 0.0 (vehicle control), 1.3 (2x), 3.9 (6x), or 6.5 (10x) mg/kg drug suspension of buprenorphine on day 0. In the repeat-dose trials, 4 groups of 8 rats (4 male, 4 female) were dosed after surgery with the vehicle control or drug suspensions containing 1.3, 3.9, or 6.5 mg/kg of buprenorphine on day 0 and following anesthesia on days 4 and 8. Male and female rats were provided with a single dose of drug and sampled at time intervals from 8 hours to 9 days to measure blood concentrations of buprenorphine.	./cache/cord-275889-4qwp3um1.txt	./txt/cord-275889-4qwp3um1.txt